It didn't fail P34 May 2020 18:15
FDA needed more data. mtfb were so confident they didn't budget for it. That's why it's on its knees even at 10p and GL gets a hard time. FDA needed more info on liver tovixity even though the liver returns to normal after treatment (mtfb couldn't afford to do that). Any other LTH want to pitch in? This all happened before CV19, when the biggest threat to mankind was bacteria not bothered by our FDA approved AB drugs. mtfb had a new AB that was extremely promising apart from the afore mentioned.